Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Merck’s stock has declined by close to 10% since early February after the WHO declared the coronavirus a global health emergency, while Eli Lilly stock has fared much better and gained 15%. The ...

Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) are both among the largest biopharmaceutical businesses in the world, but their growth prospects aren't exactly the same. Nonetheless, the pair handily ...

Pharmaceutical heavyweights Merck & Co. Inc. (NYSE: MRK) and Eli Lilly and Company (NYSE: LLY) are getting a lot of attention after outperforming the market by a mile in 2018. Both stocks have ...

2. Merck Is More Profitable . Eli Lilly’s operating margin of 24.5% over the last twelve-month period is slightly lower than 33.0% for Merck. This compares with 21.8% and 18.7% figures seen in ...

Issuing its Q2 earnings review for biopharma, Barclays has picked Eli Lilly (LLY) and Merck (MRK) as its top picks heading into the earnings season. Read more here.

January was a big month for pharmaceutical stocks, with Merck (MRK 0.15%), Eli Lilly (LLY-2.40%), and Novo Nordisk (NVO 1.18%) all climbing 11%, according to data provided by S&P Global Market ...

As for Eli Lilly, whose share price jumped 32% in 2022, the company is riding a wave of momentum as it approaches a year where it could score four FDA approvals—including high-profile nods to ...

Pharmaceutical heavyweights Merck & Co. Inc. (NYSE: MRK) and Eli Lilly and Company (NYSE: LLY) are getting a lot of attention after outperforming the market by a mile in 2018.

Pharmaceutical heavyweights Merck & Co. Inc. (MRK-0.26%) and Eli Lilly and Company (LLY 3.78%) are getting a lot of attention after outperforming the market by a mile in 2018. Both stocks have ...